These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 18393827)

  • 1. Cellular and molecular mechanisms involved in the action of vitamin D analogs targeting vitiligo depigmentation.
    Birlea SA; Costin GE; Norris DA
    Curr Drug Targets; 2008 Apr; 9(4):345-59. PubMed ID: 18393827
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New insights on therapy with vitamin D analogs targeting the intracellular pathways that control repigmentation in human vitiligo.
    Birlea SA; Costin GE; Norris DA
    Med Res Rev; 2009 May; 29(3):514-46. PubMed ID: 19241402
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Noncalcemic actions of vitamin D receptor ligands.
    Nagpal S; Na S; Rathnachalam R
    Endocr Rev; 2005 Aug; 26(5):662-87. PubMed ID: 15798098
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vitamin D receptor as a drug discovery target.
    Pinette KV; Yee YK; Amegadzie BY; Nagpal S
    Mini Rev Med Chem; 2003 May; 3(3):193-204. PubMed ID: 12570835
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vitamin D and systemic cancer: is this relevant to malignant melanoma?
    Osborne JE; Hutchinson PE
    Br J Dermatol; 2002 Aug; 147(2):197-213. PubMed ID: 12174089
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of vitamin D in melanogenesis with an emphasis on vitiligo.
    AlGhamdi K; Kumar A; Moussa N
    Indian J Dermatol Venereol Leprol; 2013; 79(6):750-8. PubMed ID: 24177606
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vitamin D analogs: mechanism of action and therapeutic applications.
    Nagpal S; Lu J; Boehm MF
    Curr Med Chem; 2001 Nov; 8(13):1661-79. PubMed ID: 11562285
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting the vitamin D endocrine system (VDES) for the management of inflammatory and malignant skin diseases: An historical view and outlook.
    Reichrath J; Zouboulis CC; Vogt T; Holick MF
    Rev Endocr Metab Disord; 2016 Sep; 17(3):405-417. PubMed ID: 27447175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trends in Regenerative Medicine: Repigmentation in Vitiligo Through Melanocyte Stem Cell Mobilization.
    Birlea SA; Costin GE; Roop DR; Norris DA
    Med Res Rev; 2017 Jul; 37(4):907-935. PubMed ID: 28029168
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of IL-17A receptor blocking in melanocyte survival: A strategic intervention against vitiligo.
    Bhardwaj S; Bhatia A; Kumaran MS; Parsad D
    Exp Dermatol; 2019 Jun; 28(6):682-689. PubMed ID: 30120811
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic applications for novel non-hypercalcemic vitamin D receptor ligands.
    Choi M; Makishima M
    Expert Opin Ther Pat; 2009 May; 19(5):593-606. PubMed ID: 19441936
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunomodulatory effects of vitamin D receptor ligands in autoimmune diseases.
    Adorini L
    Int Immunopharmacol; 2002 Jun; 2(7):1017-28. PubMed ID: 12188026
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumor effects of vitamin D analogs on hamster and mouse melanoma cell lines in relation to melanin pigmentation.
    Wasiewicz T; Szyszka P; Cichorek M; Janjetovic Z; Tuckey RC; Slominski AT; Zmijewski MA
    Int J Mol Sci; 2015 Mar; 16(4):6645-67. PubMed ID: 25811927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The importance of stereochemistry on the actions of vitamin D.
    Chiellini G; DeLuca HF
    Curr Top Med Chem; 2011; 11(7):840-59. PubMed ID: 21291397
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Challenge and perspective: the relevance of ultraviolet (UV) radiation and the vitamin D endocrine system (VDES) for psoriasis and other inflammatory skin diseases.
    Reichrath J; Saternus R; Vogt T
    Photochem Photobiol Sci; 2017 Mar; 16(3):433-444. PubMed ID: 28054069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced coactivator binding and transcriptional activation of mutant vitamin D receptors from patients with hereditary 1,25-dihydroxyvitamin D-resistant rickets by phosphorylation and vitamin D analogs.
    Liu Y; Shen Q; Malloy PJ; Soliman E; Peng X; Kim S; Pike JW; Feldman D; Christakos S
    J Bone Miner Res; 2005 Sep; 20(9):1680-91. PubMed ID: 16059639
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic application of vitamin D receptor ligands: an updated patent review.
    Takada I; Makishima M
    Expert Opin Ther Pat; 2015; 25(12):1373-83. PubMed ID: 26402335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vitamin D endocrine system and psoriasis vulgaris--review of the literature.
    Rucević I; Barisić-Drusko V; Glavas-Obrovac L; Stefanić M
    Acta Dermatovenerol Croat; 2009; 17(3):187-92. PubMed ID: 19818218
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiproliferative Activity of Non-Calcemic Vitamin D Analogs on Human Melanoma Lines in Relation to VDR and PDIA3 Receptors.
    Wasiewicz T; Piotrowska A; Wierzbicka J; Slominski AT; Zmijewski MA
    Int J Mol Sci; 2018 Aug; 19(9):. PubMed ID: 30200275
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolism of 2α-[2-(tetrazol-2-yl)ethyl]-1α,25-dihydroxyvitamin D
    Yasuda K; Tohyama E; Takano M; Kittaka A; Ohta M; Ikushiro S; Sakaki T
    J Steroid Biochem Mol Biol; 2018 Apr; 178():333-339. PubMed ID: 29425808
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.